By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Akula, Chandrashaker; Lomans, John; Tummidi, Madhukiran; Tatake, Prashant Anil, filed on September 12, 2016, was made available online on January 5, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent appl
-Research and Markets has announced the addition of the "Precision Medicine Market Analysis& Trend- Therapeutics, Application- Forecast to 2025" report to their offering. Some of the prominent trends that the market is witnessing include Next-generation monoclonal antibody-based platforms are gaining momentum in Precision Medicine, New IT technolog
-Research and Markets has announced the addition of the "Implantable Biomaterials Market Analysis& Trends- Material, Application- Forecast to 2025" report to their offering. The Global Implantable Biomaterials Market is poised to grow at a CAGR of around 7.5% over the next decade to reach approximately $165.31 billion by 2025.. With comprehensive m
Dublin- Research and Markets has announced the addition of the "Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022" report to their offering. The global platelet rich plasma market is projected to grow with a CAGR between 9.6% and 12% during 2016-2022 and reach USD 420 million by 2022.. North America is accounted as the largest
Research and Markets has announced the addition of the "Global Platelet Rich Plasma Market: Trend Analysis and Forecast to 2022" report to their offering. The global platelet rich plasma market is projected to grow with a CAGR between 9.6% and 12% during 2016-2022 and reach USD 420 million by 2022.. North America is accounted as the largest growing
Research and Markets has announced the addition of the "Transdermal Drug Delivery Market Analysis& Trends- Technology, Application- Forecast to 2025" report to their offering. The Global Transdermal Drug Delivery Market is poised to grow at a CAGR of around 11.6% over the next decade to reach approximately $95.57 billion by 2025.. Depending on th
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-101 for children impacted by Sanfilippo...
LONDON- Abzena PLC on Friday said it signed a licensing agreement with an undisclosed San Diego- based pharmaceutical company for its ThioBridge antibody drug conjugate linker technology. Shares in Abzena were up73% at 61.90 pence Friday following the announcement, the best performer on AIM. The life sciences group said it had entered into a master
Global Digestive Health Supplements Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Digestive Health Supplements industry, focusing on the main regions and the main countries. The report firstly introduced the Digestive Health Supplements basics: definitions, classifications,...
-Adamis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration has accepted for review the Companys New Drug Application for its Epinephrine Pre-filled Syringe product candidate for the emergency treatment of anaphylaxis. Filed on December 15, 2016, the resubmission was intended to address the issues raised by the FD
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the results of additional data analyses related to cognitive function from its 12- week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of MIN-101 as...
SAINT HELIER- AbbVie's blockbuster blood cancer drug Imbruvica has been approved by the FDA for yet another indication- this time, for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy. Adamis Pharmaceuticals Corp.' s resubmitted New Dr
-Aduro Biotech, Inc., a biopharmaceutical company with three distinct immunotherapy technologies, today announced an exclusive license agreement with Stanford University for state-of-the-art neoantigen identification technology developed by Dr. Hanlee Ji, associate professor of medicine at Stanford. We are excited to leverage the strength of Aduros
Research and Markets has announced the addition of the "Advanced Drug Delivery Market Analysis& Trends- Technology, Route Of Administration, End User- Forecast to 2025" report to their offering. The Global Advanced Drug Delivery Market is poised to grow at a CAGR of around 7.8% over the next decade to reach approximately $330.70 billion by 2025..
In that attempt, Congress, through budget reconciliation, would have dismantled the law by getting rid of funding for Medicaid expansion, the mandate and money for tax subsidies. According to the Iowa Policy Project report, the state could lose $446 million in federal Medicaid funding in 2019 and a total of $5.4 billion from 2019 to 2028 if the ACA
Ala-Septic Pharmaceutical Research, LLC was established in March 2009. The strategy of Ala-Septic Pharmaceutical Research, LLC has been to develop topical treatments for Pre-Melanoma Skin Cancer lesions and Melanoma Skin Cancer lesions. Ala-Septic is currently manufactured by Pure Source Labs, an FDA ap.
Jan. 19 Allegheny Health Network announced Thursday that it will offer same-day doctors' visits for people who call in the morning, a change likely aimed at distinguishing the hospital system from competitors amid trends toward more convenience in health care. Elie Aoun, AHN's medical director for clinical access. The promise of same-day visits a
By a News Reporter-Staff News Editor at Drug Week- Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has announced a research, option and license agreement with Janssen Pharmaceuticals, Inc. to develop and commercialize a novel small molecule drug candidate
Amplitude Surgical, a leading French player on the global surgical technology market for lower-limb orthopedics, today announces that it has received 510 regulatory clearance from the US Food and Drug Administration for its Anatomic implant, addressing degenerative knee disorders. Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says:
-Anavex Life Sciences Corp. and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org today announced that Rettsyndrome.org has committed a financial grant of a minimum of $0.6 million to cover the majority of a planned U.S. multicenter Phase 2 clinical trial of ANAVEX 2-73 for the treatment of Rett syndrome.
Albany, NY 01/19/2017 Transparency Market Research presents this most up-to-date research on "Aortic Valve Replacement Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016- 2024". Aortic valve is one of the two main valves on the left side of the heart and is the outflow valve for the left ventricle. It opens and cl
ARMO BioSciences, Inc., a late-stage immuno-oncology company, presented new Phase 1 b clinical data on the Company's lead investigational immuno-oncology drug AM0010 at the 2017 Gastrointestinal Cancers Symposium, co-sponsored by the American Society of Clinical Oncology, taking place January 19-21, 2017 in San Francisco, CA.. "AM0010 induces th
Release date- 19012017- East Windsor, N.J.- Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited's Ziprasidone HCl Capsules, 20 mg, 40 mg, 60 mg and 80 mg to be bioequivalent
Dr Weinberg will be based in Chicago, USA. Dr Weinberg joins Avillion from Halloran Consulting Group, a consulting firm that provides strategic guidance and development expertise to life science companies, where he was Chief Medical Officer and Managing Director. Prior to Astellas, Dr Weinberg held various positions of increasing responsibility at.
But I can now claim I have seen the FDA in the Land of Acronyms, Washington, D.C., and survived. In my case, it was the FDA, CVM Food and Drug Administration Center for Veterinary Medicine. The mental picture I had before my visit was akin to the Supreme Court or a court martial a line of wizened, beady-eyed scowling geezers wearing robes and wigs